Natalie Schüz1, Stuart G Ferguson. 1. School of Medicine, University of Tasmania, Private Bag 34, Hobart, TAS, 7001, Australia, natalie.schuez@utas.edu.au.
Abstract
RATIONALE AND OBJECTIVES: Patches are traditionally started on the day a quit attempt begins. Recently, a number of studies have established that the patch's effectiveness is improved by starting the treatment before quitting [pre-quit patch (PQP) use]. In an exploratory study, we investigate a proposed mechanism through which PQP use might promote abstinence: that PQP reduces satisfaction with smoking (either directly or via craving), which in turn leads to reduction and that smoking reduction promotes abstinence. METHODS: Fifty-seven interested quitters used handheld computers to monitor their smoking satisfaction, withdrawal and smoking in real time for 17 days, leading up to a quit attempt. All participants received 21 mg/24 h patches for 2 weeks before and for up to 10 weeks after quitting. Carbon dioxide (CO)-verified 28-day abstinence was assessed. RESULTS: During PQP treatment, participants reported significant reductions in both the satisfaction gained from smoking (p < 0.001) and their daily cigarette consumption (p < 0.001). Craving did not decrease; however, there was an interaction between time and nicotine dependence; craving decreased only among low dependent participants. Multilevel structural equation modelling revealed a direct effect of satisfaction on smoking rate. Craving did not mediate this relationship. Smoking reduction during the PQP treatment phase was not significantly associated with abstinence. CONCLUSIONS: The real-time data collection protocol utilised allowed for a fine-grained examination of smoking during PQP treatment. The results suggest that the reduction in daily cigarette smoking typically observed during PQP treatment is due to reductions in satisfaction with smoking. Unlike previous studies, however, smoking reduction was not significantly related to later abstinence, even though the odds ratio was comparably. Potential clinical implications of these findings are discussed.
RATIONALE AND OBJECTIVES: Patches are traditionally started on the day a quit attempt begins. Recently, a number of studies have established that the patch's effectiveness is improved by starting the treatment before quitting [pre-quit patch (PQP) use]. In an exploratory study, we investigate a proposed mechanism through which PQP use might promote abstinence: that PQP reduces satisfaction with smoking (either directly or via craving), which in turn leads to reduction and that smoking reduction promotes abstinence. METHODS: Fifty-seven interested quitters used handheld computers to monitor their smoking satisfaction, withdrawal and smoking in real time for 17 days, leading up to a quit attempt. All participants received 21 mg/24 h patches for 2 weeks before and for up to 10 weeks after quitting. Carbon dioxide (CO)-verified 28-day abstinence was assessed. RESULTS: During PQP treatment, participants reported significant reductions in both the satisfaction gained from smoking (p < 0.001) and their daily cigarette consumption (p < 0.001). Craving did not decrease; however, there was an interaction between time and nicotine dependence; craving decreased only among low dependent participants. Multilevel structural equation modelling revealed a direct effect of satisfaction on smoking rate. Craving did not mediate this relationship. Smoking reduction during the PQP treatment phase was not significantly associated with abstinence. CONCLUSIONS: The real-time data collection protocol utilised allowed for a fine-grained examination of smoking during PQP treatment. The results suggest that the reduction in daily cigarette smoking typically observed during PQP treatment is due to reductions in satisfaction with smoking. Unlike previous studies, however, smoking reduction was not significantly related to later abstinence, even though the odds ratio was comparably. Potential clinical implications of these findings are discussed.
Authors: Elaine Johnstone; Karen Brown; Cas Saunders; Kate Roberts; Mark Drury; Robert Walton; Mike Murphy Journal: Nicotine Tob Res Date: 2004-04 Impact factor: 4.244
Authors: Saul Shiffman; Deborah M Scharf; William G Shadel; Chad J Gwaltney; Qianyu Dang; Stephanie M Paton; Duncan B Clark Journal: J Consult Clin Psychol Date: 2006-04
Authors: Jed E Rose; Al Salley; Frederique M Behm; James E Bates; Eric C Westman Journal: Psychopharmacology (Berl) Date: 2010-04-01 Impact factor: 4.530
Authors: Saul Shiffman; Stuart G Ferguson; Chad J Gwaltney; Mark H Balabanis; William G Shadel Journal: Psychopharmacology (Berl) Date: 2005-11-01 Impact factor: 4.530
Authors: E D Levin; E C Westman; R M Stein; E Carnahan; M Sanchez; S Herman; F M Behm; J E Rose Journal: J Clin Psychopharmacol Date: 1994-02 Impact factor: 3.153
Authors: Wenying Lu; Kate Chappell; Julia A E Walters; Glenn A Jacobson; Rahul Patel; Natalie Schüz; Stuart G Ferguson Journal: Psychopharmacology (Berl) Date: 2017-03-24 Impact factor: 4.530
Authors: Daniel Romer; Stuart G Ferguson; Andrew A Strasser; Abigail T Evans; Mary Kate Tompkins; Joseph Macisco; Michael Fardal; Martin Tusler; Peters Ellen Journal: Ann Behav Med Date: 2018-01-05
Authors: Jessica W Cook; Linda M Collins; Michael C Fiore; Stevens S Smith; David Fraser; Daniel M Bolt; Timothy B Baker; Megan E Piper; Tanya R Schlam; Douglas Jorenby; Wei-Yin Loh; Robin Mermelstein Journal: Addiction Date: 2015-11-19 Impact factor: 6.526
Authors: Stuart G Ferguson; Julia A E Walters; Wenying Lu; Gudrun P Wells; Natalie Schüz Journal: BMC Public Health Date: 2015-12-21 Impact factor: 3.295